报价延迟最少15分钟:2026/04/11 11:33 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
72.56 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.59/2.33
|
|
企业价值
3.15B
|
| 资产负债 |
|
每股账面净值
8.07
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
182.95M
|
|
每股收益
0.29
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction. |
